Affibody-based nanoprobes for HER2-expressing cell and tumor imaging.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21147502.
- Also identified by DOI 10.1016/j.biomaterials.2010.11.053 and PMC identifier 3032351.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article reports the affibody-based nanoprobes specifically target and image human epidermal growth factor receptor type 2 (HER2)-expressing cells and tumors. The affibody molecules are a promising class of targeting ligands with simple, robust, and precise structure and high affinity. Using near-infrared (NIR) quantum dots (QDs) and iron oxide (IO) nanoparticles as two representative nanomaterials, we designed anti-HER2 affibody molecules with a N-terminus cysteine residue (Cysteine-Z(HER2:342)) and precisely conjugated with maleimide-functionalized nanoparticles to make nanoparticle-affibody conjugates. The in vitro and in vivo study showed the conjugates are highly specific to target and image HER2-expressing cells and tumors. This work indicated the nanoparticle-affibody conjugates may be excellent candidates as targeting probes for molecular imaging and diagnosis.
Medical subject headings
- Metal Nanoparticles
- Molecular Imaging
- Neoplasms
- Erb-b2 Receptor Tyrosine Kinases
- Recombinant Fusion Proteins